• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Bvf Partners L P/Il bought $5,301,325 worth of shares (414,105 units at $12.80) (SEC Form 4)

    11/6/23 6:07:28 PM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $KYMR alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    BVF PARTNERS L P/IL

    (Last) (First) (Middle)
    44 MONTGOMERY STREET
    40TH FLOOR

    (Street)
    SAN FRANCISCO CA 94104

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Kymera Therapeutics, Inc. [ KYMR ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) X Other (specify below)
    See Remarks and Footnotes
    3. Date of Earliest Transaction (Month/Day/Year)
    11/02/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock, $0.0001 par value(1) 11/02/2023 P 57,618 A $11.6444 2,552,306 D(2)
    Common Stock, $0.0001 par value(1) 11/02/2023 P 132,016 A $11.6444 2,020,367 D(3)
    Common Stock, $0.0001 par value(1) 11/02/2023 P 26,772 A $11.6444 284,526 D(4)
    Common Stock, $0.0001 par value(1) 11/03/2023 P 103,885 A $14.0689 2,656,191 D(2)
    Common Stock, $0.0001 par value(1) 11/03/2023 P 83,708 A $14.0689 2,104,075 D(3)
    Common Stock, $0.0001 par value(1) 11/03/2023 P 10,106 A $14.0689 294,632 D(4)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy)(5) $27.67 (6) 06/14/2033 Common Stock, $0.0001 par value 12,000 12,000 I(5) See footnote(5)
    Stock Option (Right to Buy)(5) $20 (7) 08/19/2030 Common Stock, $0.0001 par value 40,127 40,127 I(5) See footnote(5)
    Stock Option (Right to Buy)(5) $49.1 (8) 06/15/2031 Common Stock, $0.0001 par value 20,063 20,063 I(5) See footnote(5)
    Stock Option (Right to Buy)(5) $14.18 (9) 06/14/2032 Common Stock, $0.0001 par value 12,000 12,000 I(5) See footnote(5)
    1. Name and Address of Reporting Person*
    BVF PARTNERS L P/IL

    (Last) (First) (Middle)
    44 MONTGOMERY STREET
    40TH FLOOR

    (Street)
    SAN FRANCISCO CA 94104

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    BIOTECHNOLOGY VALUE FUND L P

    (Last) (First) (Middle)
    44 MONTGOMERY STREET
    40TH FLOOR

    (Street)
    SAN FRANCISCO CA 94104

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    BVF I GP LLC

    (Last) (First) (Middle)
    44 MONTGOMERY STREET
    40TH FLOOR

    (Street)
    SAN FRANCISCO CA 94104

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    BIOTECHNOLOGY VALUE FUND II LP

    (Last) (First) (Middle)
    44 MONTGOMERY STREET
    40TH FLOOR

    (Street)
    SAN FRANCISCO CA 94104

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    BVF II GP LLC

    (Last) (First) (Middle)
    44 MONTGOMERY STREET
    40TH FLOOR

    (Street)
    SAN FRANCISCO CA 94104

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Biotechnology Value Trading Fund OS LP

    (Last) (First) (Middle)
    P.O. BOX 309 UGLAND HOUSE

    (Street)
    GRAND CAYMAN E9 KY1-1104

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    BVF Partners OS Ltd.

    (Last) (First) (Middle)
    P.O. BOX 309 UGLAND HOUSE

    (Street)
    GRAND CAYMAN E9 KY1-1104

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    BVF GP HOLDINGS LLC

    (Last) (First) (Middle)
    44 MONTGOMERY STREET
    40TH FLOOR

    (Street)
    SAN FRANCISCO CA 94104

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    BVF INC/IL

    (Last) (First) (Middle)
    44 MONTGOMERY STREET
    40TH FLOOR

    (Street)
    SAN FRANCISCO CA 94104

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    LAMPERT MARK N

    (Last) (First) (Middle)
    44 MONTGOMERY STREET
    40TH FLOOR

    (Street)
    SAN FRANCISCO CA 94104

    (City) (State) (Zip)
    Explanation of Responses:
    1. This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
    2. Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.
    3. Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.
    4. Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.
    5. Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
    6. The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 15, 2024 and (ii) the date of the next annual meeting of the Issuer's stockholders.
    7. The shares subject to the option have fully vested.
    8. The shares subject to the option have fully vested.
    9. The shares subject to the option have fully vested.
    Remarks:
    For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each of the Reporting Persons may be deemed to be a director by deputization of the Issuer due to a member of Partners, Gorjan Hrustanovic, serving on the Board of Directors of the Issuer, and his agreement to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners.
    BVF Partners L.P., By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President 11/06/2023
    Biotechnology Value Fund, L.P., By: BVF I GP LLC, its general partner, By: /s/ Mark N. Lampert, Chief Executive Officer 11/06/2023
    BVF I GP LLC, By: /s/ Mark N. Lampert, Chief Executive Officer 11/06/2023
    Biotechnology Value Fund II, L.P., By: BVF II GP LLC, its general partner, By: /s/ Mark N. Lampert, Chief Executive Officer 11/06/2023
    BVF II GP LLC, By: /s/ Mark N. Lampert, Chief Executive Officer 11/06/2023
    BVF Partners OS Ltd., By: BVF Partners L.P., its sole member, By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President 11/06/2023
    Biotechnology Value Trading Fund OS LP, By: BVF Partners L.P., its investment manager, BVF Inc., its general partner, By: /s/ Mark N. Lampert, President 11/06/2023
    BVF GP Holdings LLC, By: /s/ Mark N. Lampert, Chief Executive Officer 11/06/2023
    BVF Inc., By: /s/ Mark N. Lampert, President 11/06/2023
    /s/ Mark N. Lampert 11/06/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $KYMR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KYMR

    DatePrice TargetRatingAnalyst
    3/13/2025$52.00Buy
    Citigroup
    12/10/2024$60.00Buy
    BTIG Research
    12/6/2024$55.00Market Perform
    BMO Capital Markets
    12/2/2024$57.00Equal Weight → Overweight
    Wells Fargo
    11/18/2024$65.00Overweight
    Stephens
    9/9/2024$60.00Outperform
    Leerink Partners
    8/26/2024$65.00Peer Perform → Outperform
    Wolfe Research
    4/22/2024$53.00Outperform
    Oppenheimer
    More analyst ratings

    $KYMR
    Leadership Updates

    Live Leadership Updates

    See more
    • Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases

      IRF5 program strengthens Kymera's oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug IRF5, a historically undrugged transcription factor and master regulator of immunity, has strong genetic and clinical pathway validation across multiple diseases including RA, SLE, IBD and others KT-579, a potent, selective, oral degrader of IRF5 with an excellent profile in preclinical safety studies, has demonstrated activity comparable or superior to approved and clinically active drugs in multiple efficacy animal models of lupus and RA IND-enabling studies are ongoing with Phase 1 testing expected to

      5/9/25 7:01:00 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kymera Therapeutics to Unveil New Oral Immunology Program and Report First Quarter 2025 Financial Results on May 9, 2025

      Watertown, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it will host a video webcast from 10:00 a.m. to 11:30 a.m. ET on Friday, May 9, 2025. The company will report first quarter 2025 financial results and also disclose its new oral development candidate targeting a high value undrugged target for multiple autoimmune and rheumatic diseases. Additionally, the Company will review highlights and upcoming milestones across its industry-leading immunology pipeline. To join the video call or view the li

      4/24/25 7:00:00 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer

      WATERTOWN, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Noah Goodman, M.B.A., as Chief Business Officer. Mr. Goodman brings a wealth of diverse experience in the life sciences industry to Kymera and will lead business development strategy and activities for the company. "We continue to stay focused on our mission of building a fully integrated biopharmaceutical company focused on discovering and developing oral drugs with biologics-like activity," said Nello Mainolfi, Ph.D., Founder,

      4/9/25 7:00:00 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KYMR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Baker Bros. Advisors Lp bought $46 worth of shares (1 units at $46.41) (SEC Form 4)

      4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

      8/22/24 4:03:26 PM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Bvf Partners L P/Il bought $5,301,325 worth of shares (414,105 units at $12.80) (SEC Form 4)

      4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

      11/6/23 6:07:28 PM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KYMR
    SEC Filings

    See more

    $KYMR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SEC Form 10-Q filed by Kymera Therapeutics Inc.

      10-Q - Kymera Therapeutics, Inc. (0001815442) (Filer)

      5/9/25 7:15:41 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kymera Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

      8-K - Kymera Therapeutics, Inc. (0001815442) (Filer)

      5/9/25 7:05:06 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Kymera Therapeutics Inc.

      SCHEDULE 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)

      4/30/25 11:12:25 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases

      IRF5 program strengthens Kymera's oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug IRF5, a historically undrugged transcription factor and master regulator of immunity, has strong genetic and clinical pathway validation across multiple diseases including RA, SLE, IBD and others KT-579, a potent, selective, oral degrader of IRF5 with an excellent profile in preclinical safety studies, has demonstrated activity comparable or superior to approved and clinically active drugs in multiple efficacy animal models of lupus and RA IND-enabling studies are ongoing with Phase 1 testing expected to

      5/9/25 7:01:00 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update

      Completed KT-621 (STAT6) SAD/MAD Phase 1 healthy volunteer trial with data to be reported in June 2025 First patient dosed in KT-621 (STAT6) BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) with data expected in 4Q25 KT-579 (IRF5) new oral immunology degrader program, with broad clinical potential in rheumatic and other autoimmune diseases, expected to enter Phase 1 clinical trial in early 2026 KT-474/SAR444656 (IRAK4) Phase 2b trials in HS and AD ongoing, led by partner Sanofi; Kymera achieved a $20 million milestone payment as part of the IRAK4 collaboration in April 2025 Strategic decision made not to advance KT-295 (TYK2) into further clini

      5/9/25 7:00:00 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference

      WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in a fireside chat at the BofA Securities 2025 Healthcare Conference in Las Vegas, NV on May 14, 2025, at 3:40 p.m. PT. A live webcast of the presentation will be available under "News and Events" in the Investors section of the Company's website at www.kymeratx.com. A replay of the webcast will be archived and available following the event.  About Kymera TherapeuticsKymera is a clinical-stage biotechnology company

      5/7/25 7:00:00 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KYMR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup initiated coverage on Kymera Therapeutics with a new price target

      Citigroup initiated coverage of Kymera Therapeutics with a rating of Buy and set a new price target of $52.00

      3/13/25 8:12:58 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BTIG Research initiated coverage on Kymera Therapeutics with a new price target

      BTIG Research initiated coverage of Kymera Therapeutics with a rating of Buy and set a new price target of $60.00

      12/10/24 8:28:42 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BMO Capital Markets initiated coverage on Kymera Therapeutics with a new price target

      BMO Capital Markets initiated coverage of Kymera Therapeutics with a rating of Market Perform and set a new price target of $55.00

      12/6/24 7:53:24 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KYMR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Business Officer Goodman Noah was granted 50,000 shares, increasing direct ownership by 61,396% to 50,081 units (SEC Form 4)

      4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

      4/9/25 8:05:05 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Goodman Noah claimed ownership of 81 shares (SEC Form 3)

      3 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

      4/9/25 8:00:05 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Jacobs Bruce N. exercised 25,000 shares at a strike of $2.08, increasing direct ownership by 12% to 226,886 units (SEC Form 4)

      4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

      4/1/25 8:00:03 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KYMR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Kymera Therapeutics Inc.

      SC 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)

      11/14/24 4:31:20 PM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Kymera Therapeutics Inc.

      SC 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)

      11/14/24 1:22:39 PM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Kymera Therapeutics Inc.

      SC 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)

      11/14/24 9:30:22 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KYMR
    Financials

    Live finance-specific insights

    See more
    • Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update

      Completed KT-621 (STAT6) SAD/MAD Phase 1 healthy volunteer trial with data to be reported in June 2025 First patient dosed in KT-621 (STAT6) BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) with data expected in 4Q25 KT-579 (IRF5) new oral immunology degrader program, with broad clinical potential in rheumatic and other autoimmune diseases, expected to enter Phase 1 clinical trial in early 2026 KT-474/SAR444656 (IRAK4) Phase 2b trials in HS and AD ongoing, led by partner Sanofi; Kymera achieved a $20 million milestone payment as part of the IRAK4 collaboration in April 2025 Strategic decision made not to advance KT-295 (TYK2) into further clini

      5/9/25 7:00:00 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kymera Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

      KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, complete SAD/MAD data expected in June 2025 KT-621 Phase 1b trial in atopic dermatitis (AD) patients expected to initiate in 2Q25 with data in 4Q25, followed by two parallel Phase 2b trials in AD and asthma starting in 4Q25 and 1Q26, respectively KT-295 (TYK2) Phase 1 trial is expected to start in 2Q25, with data expected in 4Q25 KT-474/SAR444656 (IRAK4) Phase 2b trials in hidradenitis suppurativa (HS) and AD ongoing, led by partner Sanofi, with primary completion of both trials expected by mid-2026 New oral degrader program against a high-value immunology target to be announced in early May 2025 in a company webcast Well-capitali

      2/27/25 7:00:00 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27

      WATERTOWN, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines with biologics-like activity for immunological diseases, will report fourth quarter and full year 2024 financial results on February 27, 2025. The Company will host a new video conference call format at 8:30 a.m. ET that day. To join the video call or view the livestreamed webcast, please register via this link, or visit "News and Events" in the Investors section of the Company's website at www.kymeratx.com. A replay of the webcast will be archived and available following the event. About Ky

      2/20/25 7:00:00 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care